Use of CAP,NP,GP in the treatment of patients with non-small cell lung cancer
- VernacularTitle:CAP、NP、GP方案治疗非小细胞肺癌临床观察
- Author:
Meiling KONG
;
Chongrui XU
;
Yong SONG
;
Yi SHI
;
- Publication Type:Journal Article
- Keywords:
Navelbine;
Gemcitabine;
Cytoxan;
Adriamycin;
Cisplatin;
Non small cell lung cancer;
Chemotherapy
- From:
Journal of Medical Postgraduates
2003;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objectives: To evaluate the efficacy, toxicity and side effects of CAP (cytoxan, adriamycin, cisplatin), NP(navelbine, cisplatin), GP(gemcitabine, cisplatin) in the treatment of patients with non small cell Lung cancer(NSCLC). Methods:146 patients with NSCLC diagnosed by pathology or cytology were treated with CAP, GP or GP regimen. Results:The overall response rate of the three groups (CAP, NP, GP)were 33.33%, 46.43% and 47.92% respectively. The major toxicity and side effects was bone marrow inhibition and the gastrointestinal reaction. Grade Ⅲ-Ⅳ side effects of CAP group were significant higher than the others. Conclusions:The regimen of navelbine and cisplatin or gemcitabine and cisplatin was more effective and less toxic than cytoxan, adriamycin, cisplatin and cisplatin.
